Biotech firm Immunic's Q3 net loss widens on higher R&D costs
IMUX•Immunic's third-quarter net loss widened to $42.3 million, or $0.99 per share, as operating and R&D expenses rose. The company expects top-line data from its Phase 3 ENSURE trial in relapsing MS in December 2026.
1. Quarterly results
Immunic reported a third-quarter net loss of $42.3 million, or $0.99 per share. Operating expenses and R&D costs increased, driven by higher personnel costs, drug supply for vidofludimus calcium and activities to prepare for a potential NDA submission.
2. Trial timeline
Immunic expects top-line data from its Phase 3 ENSURE trial in relapsing MS in December 2026. If the results are positive, the company plans a potential NDA submission for vidofludimus calcium in mid-2027; it also expects to enroll the first patient in its Phase 3 PROTECT-MS trial in progressive MS in the first half of 2027.
